ZEMVOGLI® – R Tablet

ZEMVOGLI® – R is a fixed-dose combination of Voglibose, an alpha-glucosidase inhibitor, and Repaglinide, a short-acting insulin secretagogue. It is specifically designed to control postprandial (after-meal) blood sugar spikes in adults with type 2 diabetes mellitus (T2DM). This dual approach targets both delayed carbohydrate absorption and stimulated insulin release, offering effective prandial glucose control without long-term hypoglycemia risk.

Categories: ,

Description

Composition (Each Film-Coated Tablet Contains):

  • Voglibose – 0.3 mg

  • Repaglinide – 1 mg

Category: Diabetes Care / Prandial Glucose Regulator
Form: Oral Tablet
Pack Size: 10×10 Blister / Alu-Alu


Product Description:

ZEMVOGLI® – R is a fixed-dose combination of Voglibose, an alpha-glucosidase inhibitor, and Repaglinide, a short-acting insulin secretagogue. It is specifically designed to control postprandial (after-meal) blood sugar spikes in adults with type 2 diabetes mellitus (T2DM). This dual approach targets both delayed carbohydrate absorption and stimulated insulin release, offering effective prandial glucose control without long-term hypoglycemia risk.


Key Benefits:

  • Controls blood sugar spikes after meals

  • Enhances early insulin release and delays glucose absorption

  • Reduces overall HbA1c levels

  • Low risk of prolonged hypoglycemia

  • Suitable for patients with high postprandial blood glucose


How it works:

  • Repaglinide stimulates rapid insulin secretion from pancreatic beta cells to manage glucose spikes after food intake

  • Voglibose delays carbohydrate breakdown and absorption in the small intestine by inhibiting alpha-glucosidase enzymes

Together, they offer synergistic control of postprandial hyperglycemia in type 2 diabetes.


How to use:

  • Take one tablet before each main meal, or as prescribed by your physician

  • Swallow whole with water, 15–30 minutes before food

  • Do not skip meals after taking the tablet

  • Monitor blood sugar regularly, especially after meals


Safety Advice:

  • May cause mild gastrointestinal discomfort such as bloating or flatulence (due to Voglibose)

  • Risk of hypoglycemia increases if taken without meals — always eat after dosing

  • Avoid alcohol while on this medication

  • Check blood glucose frequently in the initial weeks of therapy


Precautions:

  • Not for use in type 1 diabetes or diabetic ketoacidosis (DKA)

  • Use with caution in patients with hepatic impairment, severe GI disorders, or chronic intestinal disease

  • Not recommended during pregnancy or breastfeeding unless prescribed

  • Inform your doctor if you are taking other glucose-lowering medications or insulin


Storage:

Store in a cool, dry place below 25°C.
Keep away from moisture and direct sunlight.
Keep out of reach of children.

Reviews

There are no reviews yet.

Be the first to review “ZEMVOGLI® – R Tablet”

Your email address will not be published. Required fields are marked *